The Association for Accessible Medicines (AAM) has released the 10th edition of its annual Generic Drug Access and Savings Report that provides an outline of the savings generated by generics and biosimilars in the past year.
The Association for Accessible Medicines (AAM) has released the 10th edition of its annual Generic Drug Access and Savings Report that provides an outline of the savings generated by generics and biosimilars in the past year.
The report, which represents data derived from IQVIA, discovered that in 2017, 9 out of every 10 prescriptions in the United States were dispensed using generic drugs. However, although branded drugs only represent about 10% of prescriptions, they account for 77% of total drug spending. Additionally, savings from generics in the United States totaled $265.1 billion in 2017 alone.
At the time the report was compiled, the FDA had approved 11 biosimilars, and the report notes that there were more than 60 additional products in development. Since then, the FDA has approved another filgrastim biosimilar, to be sold as Nivestym. “Biosimilars have the potential to improve the quality of life for American patients while at the same time saving the health system billions of dollars each year—provided that the right policies are in place to nurture a robust market,” read the AAM report.
“Anybody who cares about the US healthcare system, and all the patients who depend on it, should recognize the role that generic and biosimilar medicines play in keeping people healthy and productive,” said Chester Davis, Jr., president and CEO of AAM, in a statement.
The US healthcare system—and the rising cost of drugs—have indeed generated a great deal of attention since the announcement of the Trump administration’s blueprint to lower drug prices, and polls conducted by The Kaiser Family Health Foundation have repeatedly demonstrated that drug costs are a key issue for Americans; Kaiser has found that approximately 80% of Americans think that the cost of prescription drugs is unreasonable, and 73% believe that pharmaceutical companies are making too much profit on their products.
Americans are also having a hard time paying for their medications; Kaiser found than half of Americans are taking at least 1 prescription drug, and a quarter are taking at least 4. Although most respondents (74%) reported that they can afford their medications, among those who said that they take 4 or more drugs, 35% of uninsured people younger than 65 years said that they had skipped filling a prescription because of cost, and 26% reported cutting pills in half or missing doses to save money. Those who had an income of under $40,000 per year reported the worst compliance.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.